A novel mouse model of a highly lethal form of acute myeloid leukemia (AML) offers a new tool for scientists working to better understand this disease and research new therapeutic targets. Scientists ...
SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- A demonstrated 100% concordance between biomarker-guided predictions from pre-treatment patient samples and clinical outcomes validates Yatiri Bio’s ...
Scientists at the University of Glasgow developed a bioengineered bone marrow (BM) model that helped them to evaluate potential use of a combined CRISPR-CAR T cell therapy in the treatment of acute ...
AUTX-703, a first-in-class oral KAT2A/B degrader, received FDA fast track designation for relapsed or refractory AML treatment. Promising preclinical data showed AUTX-703's effective KAT2A/B ...
Moleculin Biotech, Inc. (NASDAQ:MBRX) shares are trading higher on Wednesday after the company announced the online publication of preclinical data for its Annamycin Venetoclax Resistant AML model.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results